Echosens to Address GLP-1 Costs and Metabolic Health at SIIA National Conference 2026, Highlight Opportunities for Self-Insured Stakeholders and On-Site ClinicsWESTBOROUGH, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Echosens, a global leader in non-invasive liver diagnostics and maker of FibroScan®, announces that Shawn McGinnis, Director, Health Systems and Employer Markets, Echosens, will participate in the panel “Employers Apply the Brakes to GLP1s and Expensive Specialty Drugs.”
Understanding the Link Between NAFLD and Diabetes: Echosens Points to New AACE Guideline Supporting FibroScan as Key Component of Type 2 Diabetes Management
Echosens North America, a high-technology company offering the FibroScan® portfolio of solutions, recognizes the importance of American Diabetes Month this November for bringing greater attention to the value of non-invasive technology, such as FibroScan, to measure and monitor liver stiffness and detect nonalcoholic fatty liver disease (NAFLD). According to the American Association of Clinical Endocrinology (AACE), the risk of NAFLD, a common co-morbidity of Type 2 diabetes, is two-to-threefold higher in individuals with Type 2 diabetes mellitus and/or obesity but can be halted or reversed if detected in its earliest stages.
Echosens FibroScan® Improves Quality of Care at America’s Veterans Health Administration Facilities, Provides Early Detection and Monitoring of Liver Disease
Echosens North America, a high-technology company offering the FibroScan® portfolio of solutions, points to the critical role of FibroScan® to non-invasively measure and monitor liver stiffness and detect nonalcoholic fatty liver disease (NAFLD) among military veterans eligible to access care provided by the Veterans Health Administration (VHA). As America’s largest integrated healthcare system, the VHA provides care at 1,298 health care facilities, including 171 medical centers and 1,113 outpatient sites of care of varying complexity (VHA outpatient clinics), serving 9 million enrolled veterans each year.
Echosens and ChronWell Announce Exclusive Strategic Partnership Between FibroScan and LIVErHEALTHY to Improve Patient Outcomes and Cost Savings
Echosens North America, a high-technology company offering the FibroScan® portfolio of solutions, and ChronWell, a digital health and therapeutics company targeting metabolic conditions like non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), today announce an exclusive strategic partnership to offer LIVErHEALTHY™ in conjunction with FibroScan. Under this exclusive agreement, Echosens and ChronWell will expand digital collaboration between their platforms and co-promote FibroScan and LIVErHEALTHY, respectively, as the preferred non-invasive testing and digital therapeutic platform for NAFLD and NASH.
